Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, was investigated as a treatment for SSc in two placebo-controlled trials in patients with early inflammatory dcSSc: the phase II faSScinate trial [35] and the phase III focuSSced trial [36]. Here, IL6 is linked to systemic sclerosis.